Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 11 to 20 of 1447 total matches.

Update on Glucosamine For Osteoarthritis

   
The Medical Letter on Drugs and Therapeutics • Dec 10, 2001  (Issue 1120)
Letter, Inc. • 1000 Main Street, New Rochelle, N.Y. 10801 • A Nonprofit Publication Vol. 43 (W1120C ...
Since the last Medical Letter article on glucosamine for osteoarthritis (vol.39, page 91, September 26, 1997), more data have become available. Glucosamine is available in US pharmacies and health food stores as sulfate, hydrochloride or n-acetyl salt.
Med Lett Drugs Ther. 2001 Dec 10;43(1120):111-2 | Show Introduction Hide Introduction

Choice of Cephalosporin

   
The Medical Letter on Drugs and Therapeutics • Nov 30, 1990  (Issue 832)
, possibly because of their greater biliary excretion. AntiThe Medical Letter, Vol. 32 (Issue 832) November ...
Since the last Medical Letter review of cephalosporin antibiotics (volume 25, page 57, 1983), many new cephalosporins have become available in the USA.
Med Lett Drugs Ther. 1990 Nov 30;32(832):107-10 | Show Introduction Hide Introduction

Tiopronin for Cystinuria

   
The Medical Letter on Drugs and Therapeutics • Jan 27, 1989  (Issue 784)
and less severe than with penicillamine. The Medical Letter, Vol. 31 (Issue 784) January 27, 1989, pp. 7-8 ...
Tiopronin (Thiola - Mission), a thiol compound (mercaptopropionyl glycine) that solubilizes cystine by reacting with it to form a mixed disulfide, is now available in the USA for treatment of refractory cystinuria.
Med Lett Drugs Ther. 1989 Jan 27;31(784):7-8 | Show Introduction Hide Introduction

Propofol

   
The Medical Letter on Drugs and Therapeutics • Mar 09, 1990  (Issue 813)
may limit its use. The Medical Letter, Vol. 32 (Issue 813) March 9, 1990, p. 22 Copyright  The Medical ...
Propofol (Diprivan - Stuart), a new intravenous (IV) sedative-hypnotic, was recently marketed in the USA for induction of anesthesia, or for maintenance of general anesthesia as part of a balanced anesthesia regimen. Older drugs used in a similar way include thiopental (Pentothal; and others) and midazolam (Versed).
Med Lett Drugs Ther. 1990 Mar 9;32(813):22 | Show Introduction Hide Introduction

Pallidotomy for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Dec 06, 1996  (Issue 989)
and benefits of the procedure have not been established. The Medical Letter, Vol. 38 (Issue 989) December 6 ...
Ablation of the globus pallidus, an old treatment for Parkinsons disease, is being tried again, using more refined stereotactic techniques, improved brain imaging and new methods for recording neuronal activity (CW Olanow, Ann Neurol, 40:341, September 1996).
Med Lett Drugs Ther. 1996 Dec 6;38(989):107 | Show Introduction Hide Introduction

Extracorporeal Shock-Wave Lithotripsy for Gallbladder Stones

   
The Medical Letter on Drugs and Therapeutics • Feb 10, 1989  (Issue 785)
. All The Medical Letter, Vol. 31 (Issue 785) February 10, 1989, pp. 9-10 Copyright  The Medical Letter ...
Shock-wave generators like those now widely used to disintegrate urinary tract stones (Medical Letter, 27:72, 1985) have recently also been tried for treatment of radiolucent gallbladder stones. Three different types of lithotripsy devices, manufactured by at least eight different companies, are being used to treat gallbladder stones in multicenter trials in many locations in the USA. None of these devices has been approved for marketing by the US Food and Drug Administration.
Med Lett Drugs Ther. 1989 Feb 10;31(785):9-10 | Show Introduction Hide Introduction

Gabapentin - A New Anticonvulsant

   
The Medical Letter on Drugs and Therapeutics • Apr 29, 1994  (Issue 921)
to a saturable The Medical Letter, Vol. 36 (Issue 921) April 29, 1994, pp. 39-40 Copyright  The Medical Letter ...
Gabapentin (Neurontin - Parke-Davis), a cyclohexane acetic acid derivative, has been approved by the US Food and Drug Administration for use in addition to other antiepileptic drugs in patients with partial (focal) seizures with or without secondary generalization. Since this diagnostic category includes the largest number of patients with intractable epilepsy, new drugs with antiepileptic activity are generally tried first for this indication.
Med Lett Drugs Ther. 1994 Apr 29;36(921):39-40 | Show Introduction Hide Introduction

Implantable Cardioverter/Defibrillators (ICDs)

   
The Medical Letter on Drugs and Therapeutics • Sep 30, 1994  (Issue 932)
Letter, Vol. 36 (Issue 932) September 30, 1994, pp. 86-88 Copyright  The Medical Letter UNAUTHORIZED ...
Implanted devices that monitor cardiac rhythm and can recognize and treat ventricular tachycardia or ventricular fibrillation are now widely used in the USA and other countries. Implantable cardioverter/defibrillators (ICDs) marketed here include the Ventak P and PRX (Cardiac Pacemakers, Inc., St. Paul, MN), the PCD (Medtronic, Minneapolis, MN), and the Cadence (Ventritex, Sunnyvale, CA) (JG Porterfield et al, Am J Cardiol, 72:301, 1993).
Med Lett Drugs Ther. 1994 Sep 30;36(932):86-8 | Show Introduction Hide Introduction

Metformin for Non-Insulin-Dependent Diabetes Mellitus

   
The Medical Letter on Drugs and Therapeutics • May 12, 1995  (Issue 948)
by the kidneys without being metabolized. All of The Medical Letter, Vol. 37 (Issue 948) May 12, 1995, pp. 41-42 ...
Metformin (Glucophage - Bristol-Myers Squibb), a hypoglycemic agent, was recently marketed in the USA for oral treatment of patients with non-insulin-dependent diabetes mellitus (NIDDM) not adequately controlled by diet alone. Previously marketed in more than ninety countries, including Canada, metformin (dimethylbiguanide) is chemically related to phenformin (phenylethylbiguanide), which was withdrawn from the US market in 1976 because it caused a high incidence of lactic acidosis. In approving metformin, the US Food and Drug Administration stipulated that a post-marketing controlled...
Med Lett Drugs Ther. 1995 May 12;37(948):41-2 | Show Introduction Hide Introduction

Nalmefene - Long-Acting Injectable Opioid Antagonist

   
The Medical Letter on Drugs and Therapeutics • Oct 27, 1995  (Issue 960)
per minute, without completely antagonizing analgesia (T Radvanyi et al, Anesthesiology, Vol. 73 ...
Nalmefene (Revex - Ohmeda), an i methylene analog of naltrexone (Trexan), is a long-acting opioid antagonist that has been approved by the US Food and Drug Administration for reversal of postoperative opioid drug effects, including respiratory depression, sedation and hypotension and for management of known or suspected opioid overdose in the emergency department. The only other opioid antagonists available in the USA are naloxone (Narcan), which is also injectable but has a short duration of action, and naltrexone, which has a long duration of action but is marketed only for oral...
Med Lett Drugs Ther. 1995 Oct 27;37(960):97-8 | Show Introduction Hide Introduction